Skip to main content
WG

www.gonurlabs.com

Inactive

The startup develops a label-free and reagent-free diagnostic platform that utilizes materials science and machine learning to detect cancer early through a novel liquid biopsy method. By identifying cellular material and analyzing intercellular communication, the technology enables healthcare professionals to implement timely interventions for improved patient outcomes.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Current cancer diagnostic methods often rely on invasive biopsies and laboratory tests, which can be time-consuming, expensive, and uncomfortable for patients. Traditional liquid biopsies may require specialized reagents and labeling techniques, potentially introducing variability and limiting the scope of analysis. The lack of label-free and reagent-free methods hinders the ability to comprehensively analyze native cellular material and intercellular communication for early cancer detection.

Solution

This startup offers a diagnostic platform that leverages materials science and machine learning to detect cancer early through a novel liquid biopsy approach. The platform analyzes native cellular material and intercellular communication without the need for labels or reagents. By identifying unique biomarkers and patterns indicative of cancer, the technology enables healthcare professionals to implement timely interventions for improved patient outcomes. The platform aims to provide a more accessible, less invasive, and more comprehensive approach to cancer diagnostics.

Target Audience

The primary target audience includes healthcare professionals, oncologists, diagnostic laboratories, and research institutions involved in cancer detection and treatment.

Features

  • Label-free detection of cancer biomarkers in liquid biopsies
  • Reagent-free analysis of cellular material and intercellular communication
  • Machine learning algorithms for pattern recognition and early cancer detection
  • Proprietary materials science approach for enhanced sensitivity and specificity
  • Non-invasive alternative to traditional biopsies
  • Streamlined workflow for rapid sample processing and analysis
This profile is AI-generated and may contain inaccuracies.